| Molecule | Cat. No. | Product Name | Species | Host | Structure | Purity | Activity | Size&Price |
|---|---|---|---|---|---|---|---|---|
| CEACAM-8 | Human CEACAM-8 / CD66b Protein, His Tag, low endotoxin (MALS verified) | Human | HEK293 | ![]() | MALSSDS-PAGE | $390.00 100ug | ||
| CEACAM-8 | AvitagAIDD‑Ready CE8-H82E9 | Biotinylated Human CEACAM-8 / CD66b Protein, His,Avitag™ (SPR verified) | Human | HEK293 | ![]() | SDS-PAGE | $360.00 25ug |
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| 90Y-DTPA-besilesomab | TLX-66 | Phase 2 Clinical | Telix Pharmaceuticals Ltd | Multiple Myeloma; Neoplasms, Plasma Cell; Plasmacytoma | Details |
| English Name | Research Code | Highest Development Stage | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Besilesomab | 99Tcm-BW250-183; TLX-66-CDx; TLX66-CDx; BW-250-183 | Approved | Cis Bio International Sa | Scintimun | EU | Osteomyelitis | Cis Bio International Sa | 2010-01-11 | Osteomyelitis | Details |